Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors

Tuberculosis (TB) remains a leading cause of mortality among infectious diseases worldwide. InhA has been the focus of numerous drug discovery efforts as this is the target of the first line pro-drug isoniazid. However, with resistance to this drug becoming more common, the aim has been to find new clinical candidates that directly inhibit this enzyme and that do not require activation by the catalase peroxidase KatG, thus circumventing the majority of the resistance mechanisms. In this work, the screening and validation of a fragment library are described, and the development of the fragment hits using a fragment growing strategy was employed, which led to the development of InhA inhibitors with affinities of up to 250 nM.

[1]  V. Mizrahi,et al.  Mycobacterium tuberculosis. , 2018, Trends in microbiology.

[2]  Alimuddin Zumla,et al.  The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. , 2018, The Lancet. Respiratory medicine.

[3]  Robert H Bates,et al.  Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA , 2018, ChemMedChem.

[4]  W. Bishai,et al.  Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. , 2018, Journal of medicinal chemistry.

[5]  L. Kremer,et al.  Cyclipostins and cyclophostin analogs inhibit the antigen 85C from Mycobacterium tuberculosis both in vitro and in vivo , 2018, The Journal of Biological Chemistry.

[6]  George Papadatos,et al.  Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach , 2017, Front. Pharmacol..

[7]  Lisa K. Woolhiser,et al.  Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13 , 2017, Cell.

[8]  Jerry M. Parks,et al.  Exploring Covalent Allosteric Inhibition of Antigen 85C from Mycobacterium tuberculosis by Ebselen Derivatives. , 2017, ACS infectious diseases.

[9]  T. Blundell,et al.  Targeting tuberculosis using structure-guided fragment-based drug design. , 2017, Drug discovery today.

[10]  S. Gobec,et al.  A new 'golden age' for the antitubercular target InhA. , 2017, Drug discovery today.

[11]  D. Chan,et al.  Fragment-based approaches to TB drugs , 2016, Parasitology.

[12]  Robert H Bates,et al.  Identification of KasA as the cellular target of an anti-tubercular scaffold , 2016, Nature Communications.

[13]  J. Sacchettini,et al.  Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor , 2016, EBioMedicine.

[14]  S. Turk,et al.  Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. , 2015, Journal of medicinal chemistry.

[15]  Paul W Smith,et al.  Direct inhibitors of InhA are active against Mycobacterium tuberculosis , 2015, Science Translational Medicine.

[16]  C. Vilchèze,et al.  Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities , 2014, Microbiology spectrum.

[17]  Hongfang Yang,et al.  Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. , 2014, Journal of medicinal chemistry.

[18]  Shahul Hameed,et al.  Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. , 2013, Journal of medicinal chemistry.

[19]  J. Sacchettini,et al.  Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32 , 2013, Proceedings of the National Academy of Sciences.

[20]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[21]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[22]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[23]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[24]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[25]  Robert Stroud,et al.  Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.

[26]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[27]  Peter J Tonge,et al.  High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. , 2006, ACS chemical biology.

[28]  B. Gicquel,et al.  p-Hydroxybenzoic Acid Synthesis in Mycobacterium tuberculosis* , 2005, Journal of Biological Chemistry.

[29]  G. Fogliatto,et al.  WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.

[30]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[31]  J. D. Douglas,et al.  Antimycobacterial Activities of Isoxyl and New Derivatives through the Inhibition of Mycolic Acid Synthesis , 1999, Antimicrobial Agents and Chemotherapy.

[32]  A. Palmer,et al.  A Relaxation-Compensated Carr−Purcell−Meiboom−Gill Sequence for Characterizing Chemical Exchange by NMR Spectroscopy , 1999 .

[33]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.